Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F16%3A10332500" target="_blank" >RIV/00064203:_____/16:10332500 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/16:10332500
Result on the web
<a href="http://dx.doi.org/10.18632/oncotarget.10028" target="_blank" >http://dx.doi.org/10.18632/oncotarget.10028</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.18632/oncotarget.10028" target="_blank" >10.18632/oncotarget.10028</a>
Alternative languages
Result language
angličtina
Original language name
Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines
Original language description
In order to select a suitable combination of cancer cell lines as an appropriate source of antigens for dendritic cell-based immunotherapy of ovarian cancer, we analyzed the expression level of 21 tumor associated antigens (BIRC5, CA125, CEA, DDX43, EPCAM, FOLR1, Her-2/neu, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, MUC-1, NY-ESO-1, PRAME, p53, TPBG, TRT, WT1) in 4 established ovarian cancer cell lines and in primary tumor cells isolated from the high-grade serous epithelial ovarian cancer tissue. More than 90% of tumor samples expressed very high levels of CA125, FOLR1, EPCAM and MUC-1 and elevated levels of Her-2/neu, similarly to OVCAR-3 cell line. The combination of OV-90 and OVCAR-3 cell lines showed the highest overlap with patients' samples in the TAA expression profile.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EC - Immunology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NT14533" target="_blank" >NT14533: Role of tumor specific immune response and circulating tumour cells in the peripheral blood for the clinical course of ovarian cancer.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Oncotarget
ISSN
1949-2553
e-ISSN
—
Volume of the periodical
7
Issue of the periodical within the volume
29
Country of publishing house
US - UNITED STATES
Number of pages
7
Pages from-to
46120-46126
UT code for WoS article
000385402300098
EID of the result in the Scopus database
2-s2.0-84979946051